Cargando…
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia
Proprotein convertase-subtilisin/kexin type 9 (PCSK9) monoclonal antibody is a new therapy to reduce low-density lipoprotein cholesterol (LDL-C) level in patients with familial hypercholesterolemia (FH). This pooled analysis aimed to estimate the efficacy and safety of PCSK9 antibody therapy in FH....
Autores principales: | Li, Bin, Hao, Pan-Pan, Zhang, Yong, Yin, Rui-Hong, Kong, Qing-Zan, Cai, Xiao-Jun, Zhao, Zhuo, Qi, Jian-Ni, Li, Ying, Xiao, Jie, Wang, Fu, Yi, Wei, Ji, Xiao-Ping, Su, Guo-Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444755/ https://www.ncbi.nlm.nih.gov/pubmed/27458166 http://dx.doi.org/10.18632/oncotarget.10762 |
Ejemplares similares
-
The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022) -
Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015) -
Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
por: Li, Chuanwei, et al.
Publicado: (2015) -
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)